Related Experiment Video

Updated: Aug 19, 2026

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

Plasma atrial natriuretic peptide is elevated in patients with hypertrophic cardiomyopathy

G J Fahy1, C J McCreery, F O'Sullivan

  • 1Department of Cardiology, University College, Dublin, Ireland.

International Journal of Cardiology
|July 26, 1996
PubMed

Insights

Plasma levels of atrial natriuretic peptide (ANP) are elevated in patients with hypertrophic cardiomyopathy. However, ANP levels did not correlate with disease severity or symptoms in this patient group.

Area of Science:

  • Cardiology
  • Biochemistry
  • Medical Research

Background:

  • Hypertrophic cardiomyopathy (HCM) is a primary cardiac condition.
  • Atrial natriuretic peptide (ANP) plays a role in cardiovascular regulation.

Purpose of the Study:

  • To investigate elevated plasma atrial natriuretic peptide (ANP) in hypertrophic cardiomyopathy (HCM) patients.
  • To assess the relationship between ANP levels and clinical/echocardiographic indicators in HCM.

Main Methods:

  • Prospective study comparing ANP levels in 14 HCM patients and 17 healthy controls.
  • Echocardiography to assess left ventricular structure and diastolic function.
  • Clinical evaluation of all participants.

Main Results:

  • Significantly higher plasma ANP concentrations in HCM patients versus controls (17.86 ± 8.72 vs. 6.22 ± 3.26 pmol/l, P = 0.0001).
  • Diastolic dysfunction present in 11 of 14 HCM patients.
  • No correlation found between ANP levels and diastolic dysfunction, cardiac structure, or functional class.

Conclusions:

  • Plasma ANP levels are elevated in patients diagnosed with hypertrophic cardiomyopathy.
  • Elevated ANP in HCM does not correlate with symptoms or echocardiographic measures of cardiac structure and diastolic function.
Abstract

More Related Videos

Isolation of Atrial Myocytes from Adult Mice08:34

Isolation of Atrial Myocytes from Adult Mice

Published on: July 25, 2019

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension10:03

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension

Published on: June 27, 2025

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...